Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Neutral

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Leading Out in Developing Fresh Wave of Inhibitor Classes

Preclinical PNKP inhibitor developer burns cash and raises capital while marketing AI oncology partnerships to a niche market.

By The Northwire Desk — AI Analysis Jun 25, 2026 · 08:30 ONCO · 0.81 ONCO-INNOVATIONS LIMITED
Executive Summary
  • Most recent release (June 25, 2026): Editorial placement in BioMedWire highlighting the commercial growth of next-generation DNA Damage Response (DDR) inhibitors, noting a $7B+ market in 2025 and a ~$750B projected market by 2030. Positions ONC010 within this therapeutic shift. No new clinical, financial, or operational data is disclosed.
  • June 23, 2026: Services agreement with Nanosoft Polymers to advance polymer process development, analytical characterization, scale-up, and formulation optimization for ONC010. Aims to de-risk IND-enabling activities and GMP readiness.
  • June 19, 2026: Closed a $5M non-brokered private placement at $0.7392/unit. Also announced completion of a 300-gram API scale-up batch (99.3% purity) and appointment of Dave Antony as CFO.
  • Historical progression (March–June 2026): Continuous CMC scale-up (B4 precursor, A83, API), AI/computational collaborations (Kuano, AstraZeneca, GSK, OneMedNet), and repeated equity raises to fund operations. Management consistently guides toward IND filing and first-in-human trials in 2026/2027.
Material Impact
  • The June 25 editorial is a marketing/IR placement. It provides industry context but does not alter the company's clinical trajectory, financial position, or regulatory pathway.
  • The June 19 financing provides ~$5M in gross proceeds, extending operational runway, but at a significant discount to prior placements ($1.40 in Oct 2025, $0.88 in Jan 2026). This reflects downward valuation pressure and continued dilution.
  • The 300g API milestone and Nanosoft partnership are routine CMC and formulation steps for a preclinical candidate. They confirm manufacturing progress but do not de-risk clinical efficacy, safety, or regulatory approval.
  • Overall, the news is incremental and expected for a cash-burning preclinical biotech. It does not contain genuinely new, market-moving information that would re-rate the business.
ONCO · Price
Company Overview
  • Preclinical-stage biotechnology company developing ONC010, a nanoparticle-encapsulated PNKP inhibitor targeting DNA repair pathways in solid tumors.
  • Wholly-owned subsidiary Inka Health Corp. advances SynoGraph, an AI-driven precision oncology platform leveraging multimodal data for clinical outcome prediction.
  • Partnerships include Dalton Pharma Services (CMC/scale-up), Nucro-Technics (preclinical/bioanalysis), Avance Clinical (clinical planning), and AI/data collaborations with AstraZeneca, GSK, OneMedNet, and Kuano.
  • Strategic goal: File IND, initiate Phase 1 first-in-human trials, and pursue a U.S. exchange cross-listing.
Read the original news release →

More from ONCO-INNOVATIONS LIMITED

Jun 30, 2026 · 19:00

Preclinical-stage PNKP inhibitor developer pivots to performance-based financing amid liquidity constraints.

Financings Jun 30, 2026 · 18:00

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

M&A / Property Jun 26, 2026 · 18:00

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010

Other Jun 26, 2026 · 08:30

Canadian preclinical-stage oncology company developing PNKP inhibitor ONC010 and AI-driven SynoGraph platform.

Other Jun 23, 2026 · 18:00

Preclinical Oncology Developer Secures Polymer Partner to De-Risk ONC010 Manufacturing Ahead of IND Filing

M&A / Property Jun 19, 2026 · 19:00

Onco-Innovations Announces Non-Brokered LIFE Offering

Financings